Published on
June 19, 2020

Headlines | June 19

Companies Mentioned
No items found.
People Mentioned


Market performance of featured publicly-listed psychedelic companies for the week of June 15th - 19th.


Champignon Brands ($SHRM | $SHRMF | $496) CEO Dr. Roger McIntyre and the Canadian Rapid Treatment Centre of Excellence were recently published in two peer reviewed study journals focusing on ketamine's safety, tolerability and effectiveness. Press Release
MindMed ($MMED | $MMEDF) will now pursue DMT, the principally active ingredient in Ayahuasca, as part of its R&D collaboration with the University Hospital Basel's Liechti Lab, providing startup funding for a Phase 1 clinical trial expected to begin in Q4 of 2020. Press Release
Mydecine Innovations Group ($MYCO | $MYCOF | $0NF) has signed a definitive agreement to acquire 100% of Mindleap Health Inc. Press Release
NeonMind Biosciences, a wholly-owned subsidiary of The Yield Growth Corp ($BOSS | $BOSQF | $YG3), filed a provisional patent application related to the administration of DMT in treating compulsive eating disorder and other illnesses. Press Release
New Wave Holdings Corp. ($SPOR | $TRMND | $0XM2) added internationally recognized psychedelic medicine expert Dr. Dennis McKenna to their Psychedelic Research Advisory Board. Press Release

View All News


Rick Doblin, the founder and executive director of MAPS, was a guest on The Tim Ferriss Show. Link
The Psychedelic Science Review highlighted four studies examining the effects of psilocybin on depression and anxiety in cancel patients. Link
Psychedelic Finance interviewed Dr. Michael Verbora, Medical Director of Field Trip Psychedelics. Link. Field Trip also entered in to a letter of intent on a going-public transaction. Press Release


View Spotlight Interviews

View Companies